共有 1 页
品牌 | 货号 | 包装单位 | 货期 | 产品名称 | 质量规格 | 单价(¥) | 购买数量 |
---|---|---|---|---|---|---|---|
罗恩 | R012403-50mg | 50mg | 5~7个工作日 |
依普罗沙坦甲磺酸盐 Eprosartan Mesylate |
99% |
|
|
罗恩 | R012403-250mg | 250mg | 5~7个工作日 |
依普罗沙坦甲磺酸盐 Eprosartan Mesylate |
99% |
|
|
阿拉丁 | E129480-50mg | 50mg | 现货 |
依普罗沙坦甲磺酸盐 Eprosartan Mesylate |
≥99% |
|
|
阿拉丁 | E129480-250mg | 250mg | 现货 |
依普罗沙坦甲磺酸盐 Eprosartan Mesylate |
≥99% |
|
|
阿拉丁 | E129480-1g | 1g | 期货,请咨询 |
依普罗沙坦甲磺酸盐 Eprosartan Mesylate |
≥99% |
|
|
阿拉丁 | E421622-1ml | 1ml | 现货 |
依普罗沙坦甲磺酸盐 Eprosartan Mesylate |
10mM in DMSO |
|
|
凯为 | JZ001K03-5g | 5g | 期货,请咨询 |
依普罗沙坦甲磺酸盐 2-Thiophenepropanoic acid, α... |
99% |
|
|
凯为 | JZ001K03-25g | 25g | 现货 |
甲磺酸依普罗沙坦 Eprosartan mesylate |
99% |
|
|
毕得 | BD127397-1g | 1g | 现货 |
(E)-4-((2-丁基-5-(2-羧基-3-(噻吩-2... (E)-4-((2-Butyl-5-(2-carboxy... |
99% |
|
|
毕得 | BD127397-5g | 5g | 现货 |
(E)-4-((2-丁基-5-(2-羧基-3-(噻吩-2... (E)-4-((2-Butyl-5-(2-carboxy... |
99% |
|
|
毕得 | BD127397-250mg | 250mg | 现货 |
(E)-4-((2-丁基-5-(2-羧基-3-(噻吩-2... (E)-4-((2-Butyl-5-(2-carboxy... |
99% |
|
|
毕得 | BD127397-100mg | 100mg | 现货 |
(E)-4-((2-丁基-5-(2-羧基-3-(噻吩-2... (E)-4-((2-Butyl-5-(2-carboxy... |
99% |
|
|
梯希爱 | E1161-200MG | 200MG | 现货 |
依普罗沙坦甲磺酸盐 Eprosartan Mesylate |
98.0% |
|
|
梯希爱 | E1161-1G | 1G | 现货 |
依普罗沙坦甲磺酸盐 Eprosartan Mesylate |
98.0% |
|
|
Dr.Ehrenstorfer | C13188000 | 100mg | 期货,请咨询 |
甲磺酸依普罗沙坦 Eprosartan mesylate |
|
|
|
TRC | E590105-10mg | 10mg | 期货,请咨询 |
甲磺酸依普罗沙坦 Eprosartan Mesylate |
>95% |
|
|
Matrix | MA097737-250mg | 250mg | 3-4周 |
Eprosartan mesylate Eprosartan mesylate |
95+% | 咨询 | 请联系客服购买! |
Matrix | MA097737-1g | 1g | 3-4周 |
Eprosartan mesylate Eprosartan mesylate |
95+% | 咨询 | 请联系客服购买! |
USP | 1238217 | EA | 4周 |
Eprosartan Mesylate (50 mg) ... Eprosartan Mesylate (50 mg) ... |
标准品 |
|
|
安耐吉 | E1201550010 | 1g | 现货 |
甲磺酸依普罗沙坦 Eprosartan mesylate |
98% |
|
|
安耐吉 | E1201550050 | 5g | 期货,请咨询 |
甲磺酸依普罗沙坦 Eprosartan mesylate |
98% |
|
|
安耐吉 | E1201550250 | 25g | 期货,请咨询 |
甲磺酸依普罗沙坦 Eprosartan mesylate |
98% |
|
|
源叶 | S70339-250mg | 250mg | 现货 |
甲磺酸依普罗沙坦 Eprosartan Mesylate |
98% |
|
|
源叶 | S70339-1g | 1g | 现货 |
甲磺酸依普罗沙坦 Eprosartan Mesylate |
98% |
|
|
源叶 | S70339-5g | 5g | 现货 |
甲磺酸依普罗沙坦 Eprosartan Mesylate |
98% |
|
|
源叶 | S70339-25g | 25g | 期货,请咨询 |
甲磺酸依普罗沙坦 Eprosartan Mesylate |
98% |
|
|
源叶 | T90329-1ml | 1ml | 期货,请咨询 |
依普罗沙坦甲磺酸盐 Eprosartan Mesylate |
10mM in DMSO |
|
|
Target Mol | T2531-10mg | 10mg | 现货 |
甲磺酸依普罗沙坦 Eprosartan Mesylate |
99.93% |
|
|
Target Mol | T2531-50mg | 50mg | 现货 |
甲磺酸依普罗沙坦 Eprosartan Mesylate |
99.93% |
|
|
Target Mol | T2531-100mg | 100mg | 现货 |
甲磺酸依普罗沙坦 Eprosartan Mesylate |
99.93% |
|
|
Target Mol | T2531-200mg | 200mg | 现货 |
甲磺酸依普罗沙坦 Eprosartan Mesylate |
99.93% |
|
|
Target Mol | T2531-1mL | 1mL | 现货 |
甲磺酸依普罗沙坦 Eprosartan Mesylate |
99.93% |
|
|
Target Mol | T2531-25mg | 25mg | 现货 |
甲磺酸依普罗沙坦 Eprosartan Mesylate |
99.93% |
|
|
Target Mol | T2531-500mg | 500mg | 现货 |
甲磺酸依普罗沙坦 Eprosartan Mesylate |
99.93% |
|
|
QCC | QE192000M | 100mg | 4-6周 |
Eprosartan Mesylate Eprosartan Mesylate |
咨询 | 请联系客服购买! | |
Combi | QA-8835-1g | 1g | 请咨询 |
Eprosartan mesylate Eprosartan mesylate |
98% | 咨询 | 请联系客服购买! |
Combi | QA-8835-5g | 5g | 请咨询 |
Eprosartan mesylate Eprosartan mesylate |
98% | 咨询 | 请联系客服购买! |
Am | A217175-50mg | 50mg | 现货 |
Eprosartan mesylate Eprosartan mesylate |
99% |
|
|
Am | A217175-10mg | 10mg | 现货 |
Eprosartan mesylate Eprosartan mesylate |
99% |
|
|
Am | A217175-5mg | 5mg | 现货 |
Eprosartan mesylate Eprosartan mesylate |
99% |
|
|
Am | A217175-100mg | 100mg | 现货 |
Eprosartan mesylate Eprosartan mesylate |
99% |
|
|
Am | A217175-1g | 1g | 现货 |
Eprosartan mesylate Eprosartan mesylate |
99% |
|
|
MCE | HY-15834A-100mg | 100mg | 现货 |
Eprosartan mesylate Eprosartan mesylate |
99.85% |
|
|
MCE | HY-15834A-50mg | 50mg | 现货 |
Eprosartan mesylate Eprosartan mesylate |
99.85% |
|
|
MCE | HY-15834A-10mM*1mL | 10mM*1mL | 现货 |
Eprosartan mesylate Eprosartan mesylate |
99.85% |
|
|
MCE | HY-15834A-10mg | 10mg | 现货 |
Eprosartan mesylate Eprosartan mesylate |
99.85% |
|
|
MCE | HY-15834A-5mg | 5mg | 现货 |
Eprosartan mesylate Eprosartan mesylate |
99.85% |
|
|